– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory – – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – – Ended second quarter 2024 w ...

Century Therapeutics, Inc. (IPSC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...

文章核心观点 - 公司的CNTY-101细胞治疗产品在治疗复发或难治性非霍奇金淋巴瘤(NHL)方面显示出可管理的安全性和初步疗效 [1][3][4] - CNTY-101采用iPSC衍生的自然杀伤细胞(NK细胞)为基础,通过基因编辑技术Allo-Evasion™赋予其多项特性,如靶向CD19的嵌合抗原受体(CAR)、提高持久性的IL-15表达以及安全开关等 [2][9][10] - Allo-Evasion™技术可以帮助CNTY-101细胞逃避宿主免疫系统的识别,从而实现多次给药而不被排斥,提高治疗效果 [11] 临床试验进展 - CNTY-101在剂量递增阶段显示出可管理的安全性,未观察到剂量限制性毒性(DLT)或移植物抗宿主病(GvHD),大部分患者可在门诊环境下接受治疗 [1][4] - 在低剂量水平(1亿和3亿细胞)的初步结果中,CNTY-101显示出积极的疗效信号,包括2例完全缓解(CR)和1例部分缓解(PR) [3] - 在更高剂量水平(3亿和10亿细胞)的进一步结果显示,CNTY-101的完全缓解率(CRR)为40%,客观缓解率(ORR)为60% [6] - 采用新型细胞游离DNA(cfDNA)检测方法评估CNTY-101的药代动力学,发现其能快速从血液中转移到体内其他部位并持续存在 [7] - 临床试验正在继续剂量递增阶段,正在评估3B剂量(3次每周1亿细胞)和4A剂量(单次3亿细胞) [7] 公司概况 - 世纪治疗公司(Century Therapeutics)是一家专注于开发iPSC衍生细胞治疗的创新生物技术公司,致力于肿瘤免疫治疗和自身免疫/炎症性疾病领域 [12] - 公司正在评估CNTY-101治疗复发或难治性CD19阳性B细胞恶性肿瘤的I期ELiPSE-1临床试验,并计划启动治疗中重度系统性红斑狼疮的II期临床试验 [10]

In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single infusion of 3 ...

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that this company would post a loss of $0.56 per share when it actually produced a loss of $0.49, delivering a surprise of 12.50%.Over the last four quarters, the company has ...

Exhibit 99.1 Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delawar ...

- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 ...

Century Therapeutics公司介绍 - Century Therapeutics是一家创新的生物技术公司，专注于开发诱导多能干细胞（iPSC）衍生的细胞疗法，应用于免疫肿瘤学、自身免疫和炎症性疾病[1] - 公司管理团队将参加Chardan第八届基因药物和细胞疗法制造峰会的虚拟炉边聊天和专题讨论，主题包括“iPSCs Unleashed: Mastering Manufacturing for Next-Gen Cell Therapies”[1] - Century Therapeutics利用成体干细胞的力量开发治愈性细胞疗法产品，针对癌症、自身免疫和炎症性疾病，旨在克服第一代细胞疗法的局限性，致力于开发具有潜力克服细胞疗法固有挑战的疗法，提供明显优势[2]

公司概况 - Century Therapeutics是一家专注于开发诱导多能干细胞（iPSC）衍生的细胞疗法的生物技术公司[1] - 公司管理团队将参加Chardan第八届基因药物和细胞疗法制造峰会的虚拟炉边聊天和专题讨论[1] - 事件的回放将在公司网站的“投资者”部分的“活动和演示”页面上提供，持续90天[1] 产品研发 - Century Therapeutics正在利用成年干细胞的力量开发治愈性细胞疗法产品，旨在克服第一代细胞疗法的局限性[2] - 产品候选人经过基因工程设计，专门针对血液和实体肿瘤癌症，同时也适用于自身免疫和炎症性疾病[2] - 公司致力于开发现货细胞疗法，以扩大患者的接触范围，并提供一个无与伦比的机会来推动癌症和自身免疫和炎症性疾病护理的进程[2] 联系方式 - 欲了解更多关于Century Therapeutics的信息，请访问www.centurytx.com[2] - 投资者/媒体可通过发送电子邮件至century@argotpartners.com获取更多信息[3]